Clinical trials: Covid19 Vaccination
Influenza Immunization, Healthy Volunteers
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine…
- Trial name
- NCT04969276
- Testing
- Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
- Where
- 6 sites in United States
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
Message Communicating Latest Data on COVID-19 Transmission in Patient's Area
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned.
- Trial name
- NCT05621226
- Testing
- COVID Booster text messages
- Where
- United States
- Volunteers
- 520,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
COVID-19, SARS-CoV-2
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05477186
- Testing
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg)
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronavirus Disease 2019 (COVID-19)
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04545047
- Testing
- COVID-19 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 5,044 people
- Sponsor
- VA Office of Research and Development